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Abstract 
Cholesterol plays a critical role in liposome composition. It has great impact on the behavior 
of liposome in vitro and in vivo. In order to verify the possible effects from cholesterol charge, 
surface shielding and chemical nature, two catalogs of liposomes with charged and PEGylated 
cholesterols were synthesized. Anionic liposomes (AL) and cationic liposomes (CL) were 
prepared, with charges from hemisuccinate and lysine in cholesterol derivatives, respectively. 
Characteristics of different formulated liposomes were investigated after doxorubicin en-
capsulation, using neutral liposomes (NL) as control. Results showed that after PEGylation, AL 
and CL liposomes displayed prolonged retention release profile, while kept similar size dis-
tribution, encapsulation efficiency, low cytotoxicity and hemolysis comparing with NL. 
Confocal laser scanning microscopy and flow cytometry experiments confirmed the signifi-
cantly higher cell uptake from AL and CL vesicles than the NL in mouse breast carcinoma and 
melanoma cells, human epithelial carcinoma and hepatoma cells. It was in accordance with our 
corresponding cellular mortality studies of DOX-loaded liposomes. The in vivo anti-tumor 
effect experiments from charged liposomes also presented much higher tumor inhibition 
effect (70% vs 45%, p < 0.05) than NL liposomes. This is the first time reporting anti-cancer 
effect from charged cholesterol liposome with/without PEGylation. It may give deeper un-
derstanding on the liposome formulation which is critical for liposome associated drug re-
search and development. 
Key words: Liposome, Cholesterol derivative, charged, PEGylation, image, Drug delivery. 
1. Introduction 
Liposomes have been widely used in the thera-
peutic drug delivery, including small molecular 
drugs, proteins, genes (DNA or RNA) and diagnostic 
contrast reagents.[1-6] For example, the doxorubicin 
encapsulated liposome (Doxil) has been approved by 
FDA for ovarian cancer and Kaposi's sarcoma treat-
ment in United States over 10 years.[7]  
Although liposome has been successfully ap-
plied in the clinic, further efforts on the component 
optimization are still a hot topic in the research for 
satisfying requirements from clinic.[8-13] Changes of 
the liposomes' characteristics, including size, compo-
sition, surface properties and charge, may attribute 
for the application needed. In these factors, charge is 
believed to be one of the key factors affecting cellular 
adhesion/uptake and drug delivery.[14, 15] Normal-
ly, liposomes with cationic lipids are prone to binding 
cells than liposomes with anionic lipids due to elec-
trostatic interaction with negatively charged cell 
membrane (sialic acids and phospholipid head 
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groups). This is the reason why cationic liposomes 
were frequently used to improve in vitro and in vivo 
efficacy for drug delivery.[9-11] However, once cati-
onic liposomes were administrated into systemic cir-
culation by intravenous injection, the effect from 
blood clearance and reticuloendothelial system can-
not be ignored.[16] Meanwhile, it has been reported 
that negatively charged liposomes displayed faster 
and greater endocytosis than neutral liposomes in 
some cells.[17-20] To clarify this confusion, Dr. Dan 
applied Debye-Huckel limit of the Pois-
son–Boltzmann model to study the effect of liposome 
charge on cellular adhesion. Results showed that this 
liposome-cell interaction is determined not only from 
the lipids charge in the liposome, but also from lipids 
composition and cell types.[15] 
PEGylated lipids can contribute longer circula-
tion for liposome because of the “steric stabilization” 
effect. With the surface hydrophilic protective layer 
from PEG chain, PEGylated liposome showed char-
acterizations of more stability, sustained release, pro-
longed blood circulation time and reduced mononu-
clear phagocyte system uptake. Although the sup-
plementation of PEGylation into liposome can neu-
tralize or reduce the net zeta potential of charged lip-
osomes, the expected shielding effect in vivo was 
greatly diversified. From Dr. Torchlin’s studies, 
liposomes containing phosphatidic acid or phospha-
tidyl serine had the similar size and charge. After 
PEGylation, it was found that only phosphatidic acid 
containing vesicles could extended circulation time, 
not phosphatidyl serine. There must be other factors 
we are not clear to affect these biological 
properties.[11] 
Several studies have been reported that charac-
terization of liposome composition, including charge 
and PEGylation, may have a marked influence on the 
in vitro and in vivo behavior of the carried chemo-
therapeutics. Besides phospholipids modification, 
cholesterol is well-known to work as the framework 
in liposomal membrane, which could reduce the flu-
idity stabilize the bilayer and control the drug per-
meability properties of liposomal membrane 
bilayer.[7] In the previous cholesterol studies, most of 
the researches were focused on the content effect; few 
studies were conducted on the cholesterol itself and 
its derivatives on the behavior of liposome so far, es-
pecially for the cholesterol charges. This critical effect 
factor from charged cholesterol and surface shielding 
on liposomal behavior are deserved to be explored.  
Thus, in order to clarify this hypothesis, in this 
study, three types of cholesterol derivatives, including 
cholesterol hemisuccinate (CHEMS) with negative 
charge, lysine-based cholesterol (CHLYS) with posi-
tive charge and PEGylated cholesterol (Chol-PEG) 
without charge were synthesized. These three types of 
cholesterols were incorporated with phospholipids to 
form liposome with according surface charge. Cur-
rently, imaging techniques or modalities have been 
incorporated into drug delivery system, especially in 
the nanomedicine field.[21-25] Comparing with tradi-
tional analysis, high resolution images can not only 
provide quick and accurate information of drug be-
haviors or new materials in the period of treatment, 
but also has close relationship with drug efficacy 
which can be called as theranostics. It can facilitate the 
localization and quantization of radioisotope or opti-
cal probe labeled materials in drug delivery study and 
clinic for early diagnosis and personal medicine.[26] 
In our study, with the assistance from fluorescent 
imaging and other classic assays, Doxorubicin (DOX), 
which has therapeutic effect with strong fluorescence 
to nucleus staining, was also designed to loaded into 
this three cholesterol sourced cationic, anionic and 
neutral liposomes with/without PEGylation to com-
pare the behavior in vitro and in vivo.  
2. Materials and Methods 
2.1. Materials 
L-α-phosphatidylcholine (egg hydrogenated, 
HEPC, 99% deacetylated degree) was purchased from 
Q. P. Corporation Fine Chemical Division (Tokyo, 
Japan). Doxorubicin hydrochloride (DOX), cholesterol 
(Chol), methoxypoly(ethylene glycol) (mPEG, MW= 
2000 Da) and dicyclohexylcarbodiimide (DCC) were 
purchased from Sigma-Aldrich Chemical Co. (USA). 
Boc-protected (Boc tert-butoxycarbonyl) lysine was 
purchased from Chengdu New Technology Company 
Limited (Chengdu, China). Three cholesterol deriva-
tives (CHLYS, CHEMS and Chol-PEG) were synthe-
sized in our group. The mouse breast carcinoma 4T1 
cells, mouse melanoma B16F10 cells, human epithelial 
carcinoma Hela cells and human hepatoma HepG2 
cells were purchased from Shanghai Institute of Bio-
chemistry and Cell Biology (Chinese Academy of 
Sciences, Shanghai, China). 3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) was purchased from Sigma (St. Louis, 
MO, USA). Cell culture media (RPMI 1640), fetal bo-
vine serum (FBS), trypsin, and antibiotics were pur-
chased from Gibco BRL (USA). All the other chemicals 
of analytical grade were purchased from local com-
mercial suppliers. 
2.2. Synthesis of cholesterol derivatives 
2.2.1 Synthesis of lysine-based cholesterol (CHLYS) 
Synthesis of CHLYS was performed according to 
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our previous work with some modifications.[27] In 
brief, a solution of dicyclohexylcarbodiimide (DCC, 
0.82 g, 4 mmol) in anhydrous dichloromethane 
(CH2Cl2, 20 mL) was added dropwise to a mixed so-
lution of cholesterol (1.16 g, 3 mmol), Boc-protected 
lysine (0.69 g, 2 mmol) and a few 
4-dimethylaminopyridine (DMAP) in anhydrous 
CH2Cl2 (20 mL). The mixed solution was stirred for 2 
h at 0oC overnight at room temperature. The white 
precipitation of dicyclohexylurea (DCU) was re-
moved by filtration. Obtained filtrate was condensed 
and purified by flash chromatography on silica gel 
(CH2Cl2/MeOH 85:15, with trace TEA, Rf= 0.15) to get 
CHLYS-Boc. Trifluoroacetic acid (1 mL) was dropwise 
added to a solution of CHLYS-Boc (0.1 mmol) in an-
hydrous CH2Cl2 (1 mL) at 0oC for Boc group detach-
ment. After 2 h stirring at room temperature, product 
was concentrated and recrystallized in anhydrous 
diethyl ether, with yield of 0.36 g (71%). IR 
γ/cm−1:1738 (ester, C=O); 1HNMR (CDCl3, δ ppm): 
0.68 (s, 3H, H-18), 0.91 (s, 3H, H-21), 2.29 (d, 2H, H-4), 
3.11 (m, 2H, -CH2), 4.22 (m, 1H, -CH2-NH), 4.65 (m, 
1H, -CH), 5.08 (d, 2H, -CH2-NH), 5.38 (t, 1H, H-6). 
(Supplementary Material:  Figure S1 A) 
2.2.2 Synthesis of cholesterol hemisuccinate (CHEMS) 
Succinic anhydride (3.6 g, 36.0 mmol) was added 
to a solution of cholesterol (5.0 g, 12.9 mmol) in an-
hydrous pyridine (40 mL). The reaction mixture was 
refluxed at 90 oC under nitrogen for 24 h. The residue 
was washed with HCl/distilled ice water (5:95, v/v). 
CHEMS can be obtained by recrystallized from ace-
tone and dried under vacuum with yield of 5.3 g, 
(85%); mp 185oC. IR γ/cm−1: 1734 (ester, C=O); 1H 
NMR (CDCl3, δ ppm): 0.67 (s, 3H, H-18), 0.91 (s, 3H, 
H-21), 2.32 (d, 2H, H-4), 2.60 (m, 2H, -COCH2), 2.68 
(m, 2H, -CH2CO), 5.36 (t, 1H, H-6). (Supplementary 
Material: Figure S1 B) 
2.2.3 Synthesis of CHEMS-PEG 
According to the protocol,[28] sulfonyl chloride 
(0.67 g, 5 mmol) was added to a solution of CHEMS 
(2.4 g, 5 mmol) in 30 mL of anhydrous CH2Cl2 with 5 h 
refluxing under nitrogen stream. mPEG2000 (2 g, 1 
mmol) was added and the reaction was continued for 
another 5 h. At the end, the reaction mixture was 
condensed, and precipitated in diethyl ether thrice, 
recrystallized in anhydrous ethanol thrice and dried 
under vacuum. Dialysis was used to remove excessive 
mPEG (10 kDa cut-off), with yield of 2.2 g (88%). IR 
γ/cm−1: 1734 (ester, C=O); 1HNMR (CDCl3, δ ppm): 
0.68 (s, 3H, H-18), 0.90 (s, 3H, H-21), 2.33 (d, 2H, H-4), 
2.60 (m, 2H, -COCH2), 2.66 (m, 2H, -CH2CO), 3.37 (s, 
3H, -CH3), 3.64 (m, 176H, -OCH2O), 5.36 (t, 1H, H-6). 
(Supplementary Material: Figure S1 C) 
2.3. Preparation of various charged liposomes 
and drug loading 
Liposomes were prepared by traditional thin 
film-hydration method with different composition of 
HEPC, Chol, Chol-PEG and different charged com-
ponents (CHLYS and CHEMS), respectively. Loading 
DOX into the liposomes was carried out by the remote 
loading method with an ammonium sulfate 
gradient.[29, 30] Briefly, different composition lipids 
were dissolved in 20 mL of chloroform/methanol (3:1, 
v/v), dried into thin film by rotary evaporator and 
hydrated in 10 mL of 120 mM of ammonium sulfate 
solution. The mixture was further treated using a 
probe sonicator (UCX 130PB, sonics & materials INC., 
USA) for 2 min at 50 W. Unloaded ammonium sulfate 
was removed through dialysis against 0.9% NaCl (10 
kDa cut-off). DOX solution was added to the liposo-
mal dispersion with drug-to-lipid ratio of 1/10 (w/w) 
and incubated at 60oC for 2 h. Commonly, the lipo-
some formulations were stored at 4oC, and extruded 
through 0.22- micron filter for sterilization before use. 
2.4. Size distribution, morphology and zeta 
potential 
The particle size distribution and surface charge 
of liposomes (0.5 mg/mL) in phosphate-buffered sa-
line (PBS, pH 7.4) were measured by dynamic la-
ser-light scattering (DLS) by Zetasizer (Nano ZS, 
Malvern Instruments Ltd., UK). Liposomes were 
placed on copper grid films and stained with 2% 
(w/v) phosphotungstic acid for morphological ob-
servation by transmission electron microscopy (TEM) 
(JEM-100CX , JEOL, Japan), while dropped on silica 
slices for scanning electron microscopy (SEM) (Hita-
chi S4800, Japan) review. Surface properties of the 
liposomes were observed by atomic force microscopy 
(AFM) (MFP-3D, Asylum Research, USA) on mica 
slices. 
2.5. Drug entrapment efficiency 
Untrapped free DOX was separated from lipo-
somes by size exclusion chromatography (SEC) using 
a Sephadex G-75 column (GE Healthcare, Uppsala, 
Sweden) with UV detection at 480 nm. Liposomes 
were collected and dissolved in 10% Triton X-100 for 
the content measurement of DOX in the liposomes by 
UV-vis spectrophotometry (Lambda 650, Perkin 
Elmer, USA). The loading/entrapment efficiency was 
calculated by  
Entrapment efficiency (%)= (encapsulated drug 
in liposomes / amount of total drug) × 100%. 
Theranostics 2012, 2(11) 
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2.6. In vitro DOX release from liposomes 
Release studies were performed at 37 oC in PBS 
buffer (pH 7.4). Liposomes with a final DOX concen-
tration of 0.5 mg/mL were added into a dialysis tube 
(10 kDa cut-off), and stirred in PBS medium at 37 oC 
under perfect sink conditions. At predetermined time 
intervals, 1 mL of the medium was taken out for con-
centration detection by UV-vis spectrophotometry. 
Same volume of fresh media was fulfilled. 
2.7. Cytotoxicity study 
Cytotoxicity was determined by classic MTT as-
say. Briefly, 4T1 cells were seeded in 96-well plate at 
concentration of 5 × 103 cells/well in 1640 medium 
and cultured overnight. Drug-free liposome formula-
tions with/without 5 mol% Chol-PEG were added to 
reach a final concentration of 200 μg/mL, and incu-
bated for 24 h. Measurement was performed in mi-
croplate reader (Model 550, Bio-Rad, USA). 
2.8. Hemolysis assay 
Hemolytic activity was evaluated by determin-
ing hemoglobin release from erythrocyte after incu-
bation with different drug-free liposome formulations 
(cationic, anionic and neutral ones with/without 5 
mol% Chol-PEG). Briefly, rabbit blood samples were 
harvested from arteria auricularis into test tubes con-
taining 124 mM sodium citrate (sodium citrate: 
blood= 1: 9, v/v), centrifuged and washed with saline. 
The obtained red blood cells (RBC, 1 mL) were diluted 
with saline to 10 mL. 0.5 mL of the RBC suspension 
was incubated with 2 mL of liposomes (2.5 mg/mL) at 
37oC with gentle shaking. After 1 h, the samples were 
centrifuged at 3000 rpm for 5 min. The absorbance (A) 
of the supernatant was measured by UV-vis spectro-
photometry at 545 nm. A negative control was pre-
pared by mixing 0.5 mL of the RBC suspension with 2 
mL of saline (0% lysis), using water as a positive con-
trol (100% lysis). The absorbance value of positive 
should be 0.8 ± 0.3, while negative one should be less 
than 0.03.[31] The hemolytic rates of the samples were 
calculated as the following equation (Eq. 1): 
Hemolytic rate (%)= [(At-Anc)/ (Apc-Anc)] × 100%       
…(1) 
where At represents absorbance value of test sample, 
Anc and Apc stand for absorption value of negative and 
positive controls, respectively. 
2.9. Cellular uptake of DOX-loaded PEGylated 
liposomes 
Cellular uptake was examined by confocal laser 
scanning microscopy (CLSM, TCP SP5, Leica, Ger-
many) and flow cytometry (Cytomics FC500, Beck-
man Coulter).Various carcinoma cells including 4T1, 
B16F10, Hela and HepG2 were seeded on a 35 × 12 
mm cell culture dish (NEST Biotech Co., LTD, China) 
for CLSM view, or on 6-well plate for flow cytometry 
measurement with cell population of 1 × 106 cells. 
Drug-loaded PEGylated liposomes were added and 
incubated for 0.5, 1 and 2 h at final DOX concentration 
of 5 μg/mL. Cells were rinsed thrice with ice-cold PBS 
and observed by CLSM with excitation/emission at 
488/590 nm. In addition, cells were trypsinized and 
resuspended in 0.5 mL PBS buffer for fluores-
cence-activated cell sorting (FACS). At least 1×105 
gated events per sample were collected. 
2.10. In vitro therapeutic test 
The cellular mortality study of DOX-loaded lip-
osomes was performed against 4T1 cells on 96-well 
plate. Cells were exposed to different liposome for-
mulations at a final DOX concentration of 5 μg/mL 
for 6, 12, 24, 36 and 48h, respectively. The viability 
was detected by MTT assay using DOX solution as 
control. 
2.11. In vivo anti-tumor activity 
BALB/c mice (male, 18-22 g) were purchased 
from West China Experimental Animal Center of Si-
chuan University (China). They were maintained in a 
germ-free environment and allowed free access to 
food and water. All animal experiments were agreed 
to requirement from our IACUC and NIH guidelines 
for care and use of research animals. 5 × 105 4T1 cells 
in 50 μl sterile PBS was embedded at the left flank of 
BALB/c mice by subcutaneous injection. After the 
volume of inoculated tumor reached approximately 
100 mm3, mice were divided into 6 groups randomly 
(6 mice per group), and received different formula-
tions along with controls via tail vein injection at a 
dose of 5 mg DOX/kg body weight on the 0, 4th, 8th 
and 12th day, respectively. The transition of tumor 
volume and body weight was measured every three 
days thereafter. Tumor volume was calculated using 
Eq. (2) given below: 
V [mm3]= 1/2 × LW2          …(2) 
Where, L and W stand for the lengths in long and 
short directions of the tumors, respectively. On the 
21st days, all mice were sacrificed. Tumor inhibition 
rates were calculated according to Eq. (3) as follows: 
Tumor Inhibition Rate (TIR, %)= [(Wc- Wt)/Wc] × 
100%             …(3) 
Here Wc referred to the average weight of tumor in 
control group; Wt referred to average weight of tumor 
in treated group. 
An autopsy was performed and specimens of 
Theranostics 2012, 2(11) 
 
http://www.thno.org 
1096 
heart were collected for microscopic examination. 
Samples were fixed in 4% neutral buffered formal-
dehyde and embedded in paraffin. 5 μm thick sections 
were placed on polylysine-coated slides and stained 
with hematoxylin and eosin (H&E). The stained slides 
were pictured under microscope (BX60, Olympus, 
Japan) at 200 × magnifications. 
3. Results and discussion 
3.1. Characterization of liposomes 
Non-PEGylated liposomes, as well as PEGylated 
anionic liposomes (AL), cationic liposomes (CL) and 
neutral liposomes (NL) were prepared with according 
characterization in size distribution and zeta potential 
(Table 1). After incorporating 5 mol% of PEGylated 
component, all liposomes displayed narrower size 
distribution (all around 100 nm) than conventional 
non-PEGylated ones. The parameters of phos-
phalipids sources, ratio and charge can only influence 
the average size in a limited level. The images of SEM, 
AFM and TEM images (Figure 1A, B and C) showed 
that PEGylated AL liposomes (with or without DOX) 
was in spherical shape, and the encapsulation process 
did not affect the size and zeta potential. Similar re-
sults were obtained from DLS measurement (Table 1). 
Particles aggregation can be observed in 
non-PEGylated liposomes after one day’s storage at 
4oC, which cannot be found for PEGylated liposomes. 
As expected, zeta potential has close relationship 
with the charge on the cholesterol derivatives. Lipo-
somes prepared from HEPC/Chol (70/30, mol/mol) 
were neutral (-2.0 mV). While adding 15 mol% 
CHLYS or CHEMS, zeta potential changed to +37.2 
mV or -33.5 mV, respectively (Table 1). Introduction 
of PEG to charged liposomes reduced the absolute 
value of surface charges (from +37.2 mV to +15.2 mV, 
or from -33.5 mV to -14.6 mV, respectively). No sig-
nificant change was found in the conventional neutral 
liposomes, which was consistent with previous re-
search on the shielding effect of PEG.[32] 
 
 
Figure 1. The typical patterns of drug-free or DOX-loaded PEGylated anionic liposome (AL). (A) SEM image of drug-free AL. (B) Three di-
mensions AFM image of drug-free AL. (C) TEM image of DOX-loaded AL (bar= 200 nm). (D) The DOX release profiles from different charged 
DOX-loaded PEGylated liposomes (n= 3). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome, AL: PEGylated anionic liposome, 
DOX: free DOX). 
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Table 1. Composition, size distribution and zeta potential of liposomes. 
Liposome type * Molar radio Particle size (nm) Zeta potential (mV) Entrapment efficiency (%) 
HEPC/CHOL 70:30 151.3± 91.5† -2.0± 4.4 95.3± 4.7 
HEPC/CHOL/CHLYS 70:15:15 163.1± 101.6† 37.2± 6.2 96.7±4.5 
HEPC/CHOL/CHEMS 70:15:15 144.7± 95.1† -33.5± 5.4 95.8±5.0 
HEPC/CHOL/CHEMS-PEG (NL) 65:30:5 108.2 ± 34.2 -2.3 ± 4.4 96.6±3.9 
HEPC/CHOL/CHLYS/CHEMS-PEG (CL) 65:15:15:5 104.5 ±40.1 15.2 ± 5.8 97.3±4.8 
HEPC/CHOL/CHEMS/CHEMS-PEG (AL) 65:15:15:5 106.1 ±39.8 -14.6 ± 5.1 98.2±3.1 
*NL: PEGylated neutral liposome, CL: PEGylated cationic liposome, and AL: PEGylated anionic liposome. 
† The size distribution is abroad. 
 
3.2. Drug entrapment and in vitro DOX re-
lease from liposomes 
It was demonstrated that remote loading method 
could efficiently encapsulate DOX into liposomes, in 
which ammonium sulfate gradient existed. The higher 
intra-liposomal concentration of (NH4)2SO4 than that 
of the medium was used as the driving force for the 
influx of amphipathic weak bases, such as DOX.[29] 
In the presence of SO42-, a gel-like precipitate of DOX 
could form and be trapped inside the liposomes. Size 
exclusion chromatography was used to separate free 
DOX from DOX-loaded liposome suspension. As 
shown in the UV elution profile (Supplementary Ma-
terial: Figure S2), the small molecule of free DOX was 
eluted from 100 to 120 mL, while liposomes with di-
ameter of 100 nm were first eluted from 7.0 to 9.5 mL. 
The experiments also showed that there were no sig-
nificant differences in drug entrapment efficiency 
among the formulations (charged and neutral, with 
PEG or not). All the entrapment efficiency were as 
high as 95% (drug/lipid= 1:10, w/w) (Table 1), which 
means the surface charge and PEGylation had negli-
gible impact on DOX loading efficiency. These results 
are consistent with previous findings.[30] Addition-
ally, the PEGylated DOX-loaded liposomes can keep 
colloidal stable form for 3 months when stored at 4oC 
without any drug leakage. 
Drug release profiles studies were also per-
formed (Figure 1D). Compared with 4 h complete 
release of free DOX, the release profiles of PEGylated 
liposomes were obviously delayed post 48th h due to 
encapsulation induced retaining effect of DOX. Inter-
estingly, neutral liposomes (NL) showed a more rapid 
release at 48th h time point, while the release in both 
cationic (CL) and anionic (AL) liposomes formulation 
started at 60th h point, and reached 70~ 80% accu-
mulated release at 72nd h. The possible mechanism is 
that DOX entrapped by gradient ammonium sulfate 
may exhibit biphasic release, including slow dissolu-
tion of precipitate and membrane diffusion.[33] The 
drug release behavior was firstly governed by the 
slow precipitate dissolution rate inside liposomes, 
which led to the sustained release for a long period of 
time.[34] And then the dissolved drug could diffuse 
from the lipid membrane. During the test, precipita-
tion in dialysis tube was observed in neutral vesicles 
from about 72nd h (data not shown), resulting in the 
incomplete release of DOX. Nevertheless, charged 
liposomes (AL and CL) displayed more stable for 
their mutual repulsive force in the suspension system. 
It was assumed that after 60th h, cationic or anionic 
lipid membrane might have some structure defects 
due to higher electrostatic interactions on membrane 
permeability,[35] thus accelerating membrane diffu-
sion and leading to complete DOX release. 
3.3. Cytotoxicity study 
Various drug-free liposomes with/without 
PEGylation showed significant difference in cytotoxi-
city (Figure 2A). Without PEGylation, AL group pre-
sented much higher cellular viability (about 87%) than 
that of CL group (around 60%, p < 0.05). While after 
PEGylation, all charged liposomes showed negligible 
toxicity on 4T1 cells, remaining more than 90% viabil-
ity. It is consistent with the previous test on cationic 
vesicles.[14] 
3.4.  Hemolysis assay 
Hemolysis study was performed to investigate 
the potential toxicity after the intravenous injection of 
PEGylated AL, CL and NL in vivo. The leakage of 
hemoglobin was used to quantitatively compare the 
membrane-damaging properties of these liposomes. 
As shown in Figure 2B, the conventional 
non-PEGylated liposomes without PEG showed much 
higher extents of hemolysis rate than the PEGylated 
liposomes at 2 mg/mL concentration (p < 0.05). 
Without 5% CHEMS-PEG, NL and AL induced mild 
hemolysis (~17%) while cationic liposomes showed 
~55% hemolysis rate due to the serious destroys to red 
blood cell. These results were consistent with the 
study from Lam’s group on different charged mi-
celles.[36] It was also supported by several previous 
investigations, which indicated that the primary 
amines (positive charge) on the surface of materi-
Theranostics 2012, 2(11) 
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als/particles may induce hemolysis.[37] On the con-
trary, the hemolysis rates in all PEGylated liposomes 
were less than 5%. It is known that, PEG is a highly 
hydrated polymer and has a high degree of segmental 
flexibility in aqueous solution. Thus, PEGylation is 
commonly considered to reduce the serious cellular 
interaction,[38, 39] and consequently reduce the 
damage to red blood cell. With the improved the bi-
ocompatibility, the PEGylated liposomes could be 
further explored for anti-tumor activity, cellular up-
take and in vivo effect.  
3.5. Cellular uptake of DOX-loaded PEGylated 
liposomes 
Cellular uptake of liposomes was studied via 
confocal microscopy (Figure 3A) and flow cytometry 
analysis (Figure 3B). DOX showed the fastest cellular 
uptake and could be used for cell nucleus model be-
cause of its property of fluorescent and therapy. Fig-
ure 3A showed AL treated cells presented approxi-
mately the same fluorescence intensity as cells in CL 
group on 4T1 cells, which was much higher than that 
of NL at 2 h post-treatment. In addition, AL treated 
cells also showed the highest fluorescence intensity in 
all liposome formulations in Hela, HepG2 and B16 
cells.  
There were no obvious effects from the original 
size, morphology, cytotoxicity, encapsulation, release 
and hemolysis for PEGylated cationic and anionic 
liposomes, thus, the good cellular uptake of CL was 
likely determined by the positive charges that could 
induce electrostatic interaction with negatively 
charged cell membrane as previously reported.[40] 
Whereas observations with AL might be explained by 
Dan’s research,[15] who found cell-liposome adhesion 
depends not only on liposome charge, but also on the 
cell type and specific endocytosis. Only when the 
cell-to-liposome charge ratio (either positive or nega-
tive) reaches the appropriate range for a specific cell 
type would facilitate the liposome uptake.[17] These 
phenomena were in accordance with previous re-
search that negatively charged nanoparticles exhibit-
ed greater attraction to the macrophage and some 
tumor cells.[36, 41, 42] It might be due to distinct cell 
surface properties and specific endocytosis, since 
specific protein corona will form on the surface of 
liposomes after incubation with the cell medium.[43] 
Moreover, the quick release of DOX in the formula-
tion with CHEMS might also contribute to the higher 
fluorescence intensity in AL group.[44] The detailed 
mechanisms involved are unclear, which required 
further investigation. The FACS data displayed the 
similar results and they have high consistent with 
results from confocal images (Figure 3B). 
3.6.  In vitro cellular mortality 
In vitro anti-tumor activities of DOX-loaded 
PEGylated liposomes were evaluated via the deter-
mination of cell mortality on 4T1 tumor cells at 6th, 
12th, 24th, 36th and 48th h time point (Figure 4). Free 
DOX showed the highest cellular mortality at each 
time point, charged liposomes (CL and AL) showed 
slightly lower anti-tumor proliferation, and the rate of 
NL was the lowest one among all formulations. For 
example, at 24th h of incubation time point, cell via-
bility was about 30% for free DOX, AL and CL had 
approximately 43% of survived cells, and NL-treated 
group showed the highest cell viability of about 56% 
(p < 0.05). This was in accordance with cellular uptake 
experiment that charged liposomes had lower en-
trance than free DOX, but a greater extent of endocy-
tosis than neutral ones. 
 
Figure 2. Cytotoxicity of drug-free liposome with or without 5 mol% Chol-PEG (n= 3). (A) Cell viability of 4T1 cells after incubation with 
drug-free liposome suspension (200 μg/mL). (B) Hemolysis rate of DOX-loaded liposome suspension (2 mg/mL) (NL: PEGylated neutral liposome, 
CL: PEGylated cationic liposome and AL: PEGylated anionic liposome). 
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Figure 3. Confocal microscopic images and flow cytometry results of various cells (4T1, Hela, HepG2 and B16F10) after incubation with free 
DOX or DOX-loaded PEGylated liposomes at 37 °C for 2 h. (A) Confocal microscopic images (All the images were taken at the same fluo-
rescence intensity. bar= 25 μm) (B) Flow cytometry results. (Excitation: 488 nm; emission: 590 nm). 
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Figure. 4. Cell viability of 4T1 cells after incubation with free DOX or DOX-loaded PEGylated liposomes at a final DOX concentration of 5 
μg/mL in various incubation time (n= 5). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome and AL: PEGylated anionic liposome). 
 
3.7. In vivo anti-tumor activity 
In vivo anti-tumor activities of DOX-loaded 
PEGylated liposomes were tested using 4T1 breast 
cancer tumor-bearing BALB/c mice at a dose of 5 mg 
DOX/kg body weight. The change in the tumor 
volume was measured continuously during the ex-
periment (Figure 5A) and the tumor inhibition rates 
were compared by tumor weight after all mice were 
sacrificed (Figure 5B). The direct observation of tu-
mors excised from 4T1-bearing mice was also consid-
ered for evaluation. For the ease of graphical repre-
sentation, representative three tumors were shown in 
Figure 5C. CL and AL treated groups showed high 
tumor growth suppression with 70.9% and 68.2% (**p 
> 0.05, CL group vs AL group), respectively. Mean-
while NL and free DOX displayed less tumor inhibi-
tory effect with inhibition rate of 46.2% and 41.0%, 
respectively. Different from the inhibition results in 
vitro, DOX encapsulated in AL and CL showed im-
proved effect than free DOX in vivo (*p < 0.05 vs DOX 
group). 
Although free DOX showed good cellular up-
take, it was difficult to reach the tumor target site due 
to the rapid clearance by opsonization and uptake by 
the reticuloendothelial system.[45] Whereas DOX 
loaded liposomes could be delivered to the tumor site 
via enhanced permeability and retention effect. It was 
reported that cationic liposomes could induce signif-
icant tumor growth suppression than neutral vesicles 
and free drug, for preferential tumor accumulation.[9] 
In our study, the anti-tumor effect of PEGylated ani-
onic liposomes was comparable to cationic ones in 
vivo. It might cause by the tumor cell type or the spe-
cific structure of CHEMS. In 4T1 cells, CL and AL 
showed similar uptake, indicating 4T1 cells prefer 
both cationic and anionic liposomes. As reported by 
Hafez et al.,[35] CHEMS exhibited pH sensitive pol-
ymorphism, that when pH decreased to 5.5, CHEMS 
induced changes in the bilayer forming cylinder of 
liposome to the inverted hexagonal phase, thus ac-
celerating drug release. 
Significant toxicity was observed in the group 
only administrated with DOX. In the DOX group, ~ 
20% of body weight was found to lose in mice and 
displayed obvious no vigorousness in mice compar-
ing with controls after the 3rd and 4th i.v. injection, 
which reflected the signs of systemic toxicity from 
DOX (Supplementary Material: Figure S3, *p < 0.05 vs 
control and other liposome group). While mice treat-
ed with DOX-loaded liposomes showed none of these 
adverse effects (p > 0.05), indicating the low acute 
toxicity from the liposome formulation. 
Considering the reported damage by free DOX 
to heart, such as swollen cardiac muscle fibers, inter-
stitial edema and inflammatory infiltration,[46-48] 
histopathological investigation was conducted (Fig-
ure 5D). From the pathological data, no apparent 
changes were observed in drug-free or DOX-loaded 
liposome treatment groups. Thus, DOX-loaded 
PEGylated liposomes showed less cardiac toxicity in 
vivo as compared to free DOX. 
Nowadays, research into the rational delivery 
and targeting of pharmaceutical, therapeutic, and 
diagnostic agents is at the forefront of projects in na-
nomedicine. These diagnostics based nanoparticles 
can improve the sensitivity and specificity and help 
identify abnormalities that cannot be detected with 
traditional ways, provide more effective and/ or more 
convenient routes of administration, lower therapeu-
tic toxicity, extend the product life cycle, and ulti-
mately reduce health-care costs. In the past few years, 
a number of nanoparticle-based therapeutic and di-
agnostic agents have been developed for the treat-
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ment of cancer, diabetes, pain, asthma, allergy, and 
infections. As a complicated therapeutic delivery 
system, liposome is also one of the most successful 
nanoparticles in the market approved by FDA for the 
chemotherapeutic drug DOX loading and delivery. 
Liposome allows passive targeted delivery and con-
trolled release. With the assistance from diagnostic 
reagent or the fluorescence form the capsulated drug 
itself, liposome may be entity for drug delivery and 
medical imaging, which fit the property of nanomed-
icine with diagnostic functionality referred by the 
National Institutes of Health (NIH). The in vivo be-
havior of liposomes can be influenced by multiple 
interdependent factors. A minor change in chemical 
formulation may result in evident diversification in 
biological behavior.[33] To elucidate major factors 
that affect anti-tumor activity of CL and AL, further in 
vivo biodistribution behavior including tumor locali-
zation and elimination need to be proceeded, which 
means the studies on physiological based pharmaco-
kinetic (PBPK). DOX-loaded PEGylated charged lip-
osomes exhibited strong anti-tumor efficiency both in 
vitro and in vivo, indicating that using cholesterol de-
rivatives might be a promising approach in forming 
multi-functional liposomes for clinic. 
 
 
Figure 5. In vivo anti-tumor activity of liposomes after i.v. injection of different DOX-loaded PEGylated liposomes with a DOX concentration of 
5 mg/kg body weight (n=6). (A) The tumor volume in different treatment groups. (* p < 0.05 vs control group) (B) Tumor inhibition rates of 
various formulations. (* p < 0.05 vs DOX group, ** p > 0.05) (C) The tumor morphology after three weeks treatment of different DOX prep-
aration. (D) Mouse myocardium: treated with free DOX or DOX-loaded liposomes at a DOX concentration of 5 mg/kg body weight (H&E stain 
200×). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome and AL: PEGylated anionic liposome). 
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4. Conclusion 
In our work, doxorubicin with property of fluo-
rescence and therapy was successfully encapsulated 
into charged liposome formulations from cationic and 
anionic cholesterol derivatives. Such liposome for-
mulations can serve as a model platform to further 
study the in vitro and in vivo behavior with assistance 
from fluorescent images, FACS technique and some 
other classic methods. Our research demonstrated 
that the charged liposomes incorporating with PEG 
showed prolonged and improved release profile of 
DOX, as well as low cytotoxicity and hemolysis. In 
addition, charged liposomes, especially the anionic 
ones have significant enhancement on uptake and cell 
inhibition in various carcinoma cells than neutral 
ones. In vivo tumor inhibition further confirmed that 
charged liposomes had greater tumor inhibitory ef-
fect, indicating both positively and negatively 
charged PEGylated liposome formulations with 
modified cholesterol derivatives may be potential 
drug carriers to improve the therapeutic efficacy. 
Supplementary Material 
Fig.S1 - S3.  http://www.thno.org/v02p1092s1.pdf 
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